Table 5 Overall tophus complete response and target tophus complete response for patients in the open-label extension study a
Visit during | Biweekly pegloticase in | Monthly pegloticase in | Placebo in RCT and | All patientsc |
|---|---|---|---|---|
OLE parameterb | RCT and continued | RCT and continued | initiated pegloticase | Â |
| Â | pegloticase in OLE | pegloticase in OLE | in OLE | Â |
(n= 45) | (n= 42) | (n= 26) | (N= 113) | |
Overall CR, n/N (% patients) | ||||
Week 13 visit | 17 of 36 (47) | 12 of 28 (43) | 7 of 16 (44) | 36 of 80 (45) |
Week 25 visit | 20 of 31 (65) | 16 of 28 (57) | 11 of 15 (73) | 47 of 74 (64) |
Week 53 visit | 21 of 29 (72) | 18 of 27 (67) | 11 of 12 (92) | 50 of 68 (74) |
Week 77 visit | 17 of 27 (63) | 12 of 19 (63) | 10 of 11 (91) | 39 of 57 (68) |
Week 101 visit | 3 of 5 (60) | 3 of 3 (100) | 2 of 2 (100) | 8 of 10 (80) |
Final visit | 23 of 39 (59) | 20 of 34 (59) | 13 of 21 (62) | 56 of 94 (60) |
TT-CR, n/N (% tophi) | All target tophi (N = 357) | |||
Week 13 visit | 55 of 164 (34) | 36 of 104 (35) | 17 of 89 (19) | 108 of 357 (30) |
Week 25 visit | 67 of 136 (49) | 52 of 103 (50) | 39 of 79 (49) | 158 of 318 (50) |
Week 53 visit | 70 of 138 (51) | 62 of 100 (62) | 53 of 64 (83) | 185 of 302 (61) |
Week 77 visit | 85 of 138 (62) | 40 of 61 (66) | 51 of 62 (82) | 176 of 261 (67) |
Week 101 visit | 4 of 9 (44) | 10 of 10 (100) | 8 of 12 (67) | 22 of 31 (71) |
Final visit | 90 of 164 (55) | 68 of 121 (56) | 49 of 105 (47) | 207 of 390 (53) |